- Home
- GENK vs MRKR Comparison
GENK vs MRKR Comparison
Compare GENK & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- MRKR
- Stock Information
- Founded
- GENK 2011
- MRKR N/A
- Country
- GENK United States
- MRKR United States
- Employees
- GENK N/A
- MRKR N/A
- Industry
- GENK Restaurants
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- MRKR Health Care
- Exchange
- GENK Nasdaq
- MRKR Nasdaq
- Market Cap
- GENK 41.1M
- MRKR 35.8M
- IPO Year
- GENK 2023
- MRKR N/A
- Fundamental
- Price
- GENK $7.76
- MRKR $2.95
- Analyst Decision
- GENK Strong Buy
- MRKR Strong Buy
- Analyst Count
- GENK 3
- MRKR 1
- Target Price
- GENK $13.17
- MRKR $19.00
- AVG Volume (30 Days)
- GENK 65.2K
- MRKR 25.2K
- Earning Date
- GENK 11-12-2024
- MRKR 11-14-2024
- Dividend Yield
- GENK N/A
- MRKR N/A
- EPS Growth
- GENK N/A
- MRKR N/A
- EPS
- GENK 0.17
- MRKR N/A
- Revenue
- GENK $198,834,000.00
- MRKR $5,395,849.00
- Revenue This Year
- GENK $15.09
- MRKR $35.94
- Revenue Next Year
- GENK $20.04
- MRKR N/A
- P/E Ratio
- GENK $44.86
- MRKR N/A
- Revenue Growth
- GENK 12.50
- MRKR 79.04
- 52 Week Low
- GENK $5.61
- MRKR $2.44
- 52 Week High
- GENK $14.46
- MRKR $6.16
- Technical
- Relative Strength Index (RSI)
- GENK 39.23
- MRKR 39.64
- Support Level
- GENK $7.89
- MRKR $2.82
- Resistance Level
- GENK $8.83
- MRKR $3.25
- Average True Range (ATR)
- GENK 0.63
- MRKR 0.37
- MACD
- GENK -0.18
- MRKR -0.13
- Stochastic Oscillator
- GENK 5.17
- MRKR 8.34
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.